Vaccine · 2025
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac) in Brazilian healthcare professionals: The PROFISCOV trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moreira José, Patiño Elizabeth G, Braga Patricia Emilia, Pacheco Pedro, Curimbaba Caroline, Gast Christopher, Palacios Ricardo, Teixeira Mauro, Ramos Fabiano, Romero Gustavo, Leal Fabio, Junior Luiz, Camargo Luiz, Aoki Francisco, Coelho Eduardo, Siqueira André, Raboni Sonia, Oliveira Danise, Tarso Paulo, Fontes Cor, Lyrio Ana, Nogueira Mauricio L, Kallas Esper, PROFISCOV study group
Аннотация
BACKGROUND: CoronaVac, an inactivated COVID-19 vaccine, underwent evaluation for its efficacy and safety during the PROFISCOV study conducted in Brazil.
METHODS: Between July 21, 2020, and July 29, 2021, 13,166 participants provided informed consent, with 12,688 randomized for the trial. Participants were allocated between vaccine and placebo arms (1:1) and monitored for symptomatic COVID-19 cases, severity of disease, and adverse reactions after two doses given 14 days apart.
FINDINGS: The primary efficacy analysis revealed a vaccine efficacy of 50⸱4 % (95 % confidence interval [CI], 35·3 % to 62·0 %; p = 0·0049) in preventing symptomatic COVID-19, leading to the issuance of Emergency Use Authorization for CoronaVac in January 2021. Upon completion of follow-up, vaccine efficacy was 44⸱6 % [95 % CI, 34·9 % to 52·8 %; p = 0·0023] in preventing COVID-19 and 82⸱1 % (95 % CI, 64·9 % to 90·9 %; p < 0·0001) in preventing severe COVID-19. Safety data indicated that adverse reactions were more frequent in the vaccine arm, primarily mild to moderate, with pain at the injection site and headache being the most common.
INTERPRETATION: CoronaVac demonstrated moderate efficacy in preventing symptomatic COVID-19 and high efficacy against severe disease. While reactions were slightly more common in the vaccine group, they were generally mild and manageable.
FUNDING: Fundação Butantan, Instituto Butantan, and São Paulo Research Foundation (FAPESP; Grants 2020/10127-1 and 2020/06409-1).
METHODS: Between July 21, 2020, and July 29, 2021, 13,166 participants provided informed consent, with 12,688 randomized for the trial. Participants were allocated between vaccine and placebo arms (1:1) and monitored for symptomatic COVID-19 cases, severity of disease, and adverse reactions after two doses given 14 days apart.
FINDINGS: The primary efficacy analysis revealed a vaccine efficacy of 50⸱4 % (95 % confidence interval [CI], 35·3 % to 62·0 %; p = 0·0049) in preventing symptomatic COVID-19, leading to the issuance of Emergency Use Authorization for CoronaVac in January 2021. Upon completion of follow-up, vaccine efficacy was 44⸱6 % [95 % CI, 34·9 % to 52·8 %; p = 0·0023] in preventing COVID-19 and 82⸱1 % (95 % CI, 64·9 % to 90·9 %; p < 0·0001) in preventing severe COVID-19. Safety data indicated that adverse reactions were more frequent in the vaccine arm, primarily mild to moderate, with pain at the injection site and headache being the most common.
INTERPRETATION: CoronaVac demonstrated moderate efficacy in preventing symptomatic COVID-19 and high efficacy against severe disease. While reactions were slightly more common in the vaccine group, they were generally mild and manageable.
FUNDING: Fundação Butantan, Instituto Butantan, and São Paulo Research Foundation (FAPESP; Grants 2020/10127-1 and 2020/06409-1).